- Home
- ESPR vs GUG Comparison
ESPR vs GUG Comparison
Compare ESPR & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- GUG
- Stock Information
- Founded
- ESPR 2008
- GUG 2021
- Country
- ESPR United States
- GUG United States
- Employees
- ESPR N/A
- GUG N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- GUG Trusts Except Educational Religious and Charitable
- Sector
- ESPR Health Care
- GUG Finance
- Exchange
- ESPR Nasdaq
- GUG Nasdaq
- Market Cap
- ESPR 319.2M
- GUG 502.3M
- IPO Year
- ESPR 2013
- GUG N/A
- Fundamental
- Price
- ESPR $1.65
- GUG $16.05
- Analyst Decision
- ESPR Buy
- GUG
- Analyst Count
- ESPR 4
- GUG 0
- Target Price
- ESPR $8.17
- GUG N/A
- AVG Volume (30 Days)
- ESPR 4.1M
- GUG 108.9K
- Earning Date
- ESPR 08-12-2024
- GUG 01-01-0001
- Dividend Yield
- ESPR N/A
- GUG 9.67%
- EPS Growth
- ESPR N/A
- GUG N/A
- EPS
- ESPR N/A
- GUG N/A
- Revenue
- ESPR $277,788,000.00
- GUG N/A
- Revenue This Year
- ESPR $207.14
- GUG N/A
- Revenue Next Year
- ESPR $23.85
- GUG N/A
- P/E Ratio
- ESPR N/A
- GUG N/A
- Revenue Growth
- ESPR 215.98
- GUG N/A
- 52 Week Low
- ESPR $0.70
- GUG $12.71
- 52 Week High
- ESPR $3.40
- GUG $15.06
- Technical
- Relative Strength Index (RSI)
- ESPR 33.48
- GUG 65.95
- Support Level
- ESPR $1.73
- GUG $15.74
- Resistance Level
- ESPR $1.88
- GUG $16.18
- Average True Range (ATR)
- ESPR 0.10
- GUG 0.24
- MACD
- ESPR 0.01
- GUG 0.04
- Stochastic Oscillator
- ESPR 7.04
- GUG 84.71
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation.